Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
Emerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression and activation of histone methyltransferases (HMTs) have been reported in preclinical models of multiple kidney diseases, includ...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01393/full |
id |
doaj-b193bacb8f0647e59f81409f487b7e15 |
---|---|
record_format |
Article |
spelling |
doaj-b193bacb8f0647e59f81409f487b7e152020-11-25T01:44:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-12-011010.3389/fphar.2019.01393470433Histone Methyltransferases as Therapeutic Targets for Kidney DiseasesChao Yu0Shougang Zhuang1Shougang Zhuang2Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, United StatesEmerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression and activation of histone methyltransferases (HMTs) have been reported in preclinical models of multiple kidney diseases, including acute kidney injury, chronic kidney disease, diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma. Pharmacological inhibition of these enzymes has shown promise in preclinical models of those renal diseases. In this review, we summarize recent knowledge regarding expression and activation of various HMTs and their functional roles in some kidney diseases. The preclinical activity of currently available HMT inhibitors and the mechanisms of their actions are highlighted.https://www.frontiersin.org/article/10.3389/fphar.2019.01393/fullchronic kidney diseasesepigenetic regulationshistone modificationhistone methyltransferasesexpression |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chao Yu Shougang Zhuang Shougang Zhuang |
spellingShingle |
Chao Yu Shougang Zhuang Shougang Zhuang Histone Methyltransferases as Therapeutic Targets for Kidney Diseases Frontiers in Pharmacology chronic kidney diseases epigenetic regulations histone modification histone methyltransferases expression |
author_facet |
Chao Yu Shougang Zhuang Shougang Zhuang |
author_sort |
Chao Yu |
title |
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases |
title_short |
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases |
title_full |
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases |
title_fullStr |
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases |
title_full_unstemmed |
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases |
title_sort |
histone methyltransferases as therapeutic targets for kidney diseases |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-12-01 |
description |
Emerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression and activation of histone methyltransferases (HMTs) have been reported in preclinical models of multiple kidney diseases, including acute kidney injury, chronic kidney disease, diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma. Pharmacological inhibition of these enzymes has shown promise in preclinical models of those renal diseases. In this review, we summarize recent knowledge regarding expression and activation of various HMTs and their functional roles in some kidney diseases. The preclinical activity of currently available HMT inhibitors and the mechanisms of their actions are highlighted. |
topic |
chronic kidney diseases epigenetic regulations histone modification histone methyltransferases expression |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.01393/full |
work_keys_str_mv |
AT chaoyu histonemethyltransferasesastherapeutictargetsforkidneydiseases AT shougangzhuang histonemethyltransferasesastherapeutictargetsforkidneydiseases AT shougangzhuang histonemethyltransferasesastherapeutictargetsforkidneydiseases |
_version_ |
1725027161048350720 |